|
Age
|
44.7 ± 12.1 (19 to 73)
|
46.9 ± 10.6 (18 to 75)
|
0.175
| | |
|
<45
|
29 (54.7%)
|
104 (40.8%)
|
|
≥45
|
24 (45.3%)
|
151 (59.2%)
|
|
Multifocality
|
1.8 (1 to 11]
|
1.0 (1 to 10]
|
0.001
|
0.268
|
−0.034 to approximately 0.009
|
|
Tumor size(mm)
|
15.7 ± 10.4 (2 to 58)
|
10.5 ± 6.3 (0.5 to 38)
|
0.003
|
0.135
|
−0.010 to approximately 0.009
|
|
≤1
|
18 (34.0%)
|
143 (56.0%)
|
|
>1
|
35 (66.0%)
|
112 (44.0%)
|
|
Thyroditis
| | |
0.169
| | |
|
Present
|
14 (26.4%)
|
91 (35.7%)
|
|
Absent
|
39 (73.6%)
|
164 (64.3%)
|
|
Lymphvascular Invasion
| | |
0.001
|
0.005
|
0.047 to approximately 0.262
|
|
Present
|
30 (56.6%)
|
32 (12.5%)
|
|
Absent
|
23 (43.4%)
|
223 (87.5%)
|
|
Capsule Invasion
| | |
0.001
|
0.849
|
−0.066 to approximately ~0.080
|
|
Present
|
42 (79.2%)
|
131 (51.4%)
|
|
Absent
|
11 (20.8%)
|
124 (48.6%)
|
|
Central metastasis
|
53
|
88
|
0.001
|
0.001
|
0.157 to approximately 0.339
|
|
Contralateral central metastasis
|
28 (52.8%)
|
36 (14.1%)
|
|
Ipsilateral central metastasis
|
19 (35.8%)
|
52 (20.4%)
|
|
Non-metastasis
|
6 (11.3%)*
|
167 (65.6%)
|
|
Lateral metastasis
| | |
0.005
|
0.016
|
0.026 to approximately 0.250
|
|
Present
|
25 (47.2%)
|
26 (10.2%)
|
|
Absent
|
28 (52.8%)
|
229 (89.8%)
| | | |
